Skip to main content
LGNDZ logo

Ligand Pharmaceuticals, Inc. (LGNDZ) Stock Price & Analysis

Ligand Pharmaceuticals, Inc. (LGNDZ) — price $0.0017 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0017 $0.00 (0.00%)

Ligand Pharmaceuticals, Inc. · LGNDZ

Ligand Pharmaceuticals, Inc. It operates on a licensing and royalty-based business model, featuring products like evomela and the OmniAb platform, while currently trading on the OTC market in the 'OTC Other' tier.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0017
Change on the day0.00%
52-week range$0.0013 – $0.0095
Price / earnings (trailing)113.44
Shares traded on the day300

Price & events

Other perspectives

Council score for Ligand Pharmaceuticals (LGNDZ): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ligand Pharmaceuticals (LGNDZ), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ligand Pharmaceuticals, Inc. (LGNDZ) is the company analyzed here. It employs 47 people and is led by Todd C. Davis. In Q3 FY2026 it reported revenue of $79M and net income of -$60M.

2 · Latest results

What do the latest results show for Ligand Pharmaceuticals (LGNDZ)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $79M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$79M-$60M-$1.43 (diluted)
Q2 FY2026$64M$49M$2.22 (diluted)
Q1 FY2026$52M-$13M-$0.67 (diluted)
Q4 FY2025$60M$45M$2.12 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ligand Pharmaceuticals (LGNDZ)?

Short answer

The distress and quality screens read Altman Z 0.59 · Piotroski F 4. Trailing ratios: ROE 5.4% · ROA 1.2% · current ratio 1.22.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LGNDZ in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LGNDZ in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Ligand Pharmaceuticals (LGNDZ)

These answers are editorial: 1 of these 1 answer is drawn from the LGNDZ research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.

What are the implications of Ligand Pharmaceuticals, Inc.'s OTC Other tier listing?

Ligand Pharmaceuticals, Inc.'s listing on the 'OTC Other' tier of the OTC market carries several significant implications for investors. This tier is typically reserved for companies that do not meet the financial or disclosure standards of higher OTC tiers or major exchanges like NASDAQ or NYSE.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.